新型Ankura Plus支架与Castor支架治疗近端锚定区不足的Stanford B型主动脉夹层的比较
本研究回顾性比较了Ankura Plus支架与Castor支架治疗近端锚定区不足的Stanford B型主动脉夹层的疗效与安全性,共纳入54例患者(Ankura Plus组16例,Castor组38例)。两组手术成功率均为100%,住院期间无内漏或死亡;Ankura Plus组手术时间较长(122.6±5.1 vs. 103.7±10.0,P<0.001)。平均随访12个月,两组主支架及分支支架通畅率均为100%,真腔直径显著增加、假腔直径缩小,假腔完全血栓形成概率无统计学显著差异(68.8% vs. 67.6%,P=0.993)。结论认为两种支架均可行、安全、有效,但Ankura Plus支架需更长期研究评估其稳健性和适用性。
要点
- 两组手术成功率均为100%,住院期间无内漏或死亡。
- Ankura Plus组手术时间长于Castor组(122.6±5.1 vs. 103.7±10.0,P<0.001)。
- 平均随访12个月,两组主支架及分支支架通畅率均为100%,假腔完全血栓形成概率无统计学显著差异(68.8% vs. 67.6%,P=0.993)。
核心结论
- Ankura Plus支架与Castor支架治疗近端锚定区不足的Stanford B型主动脉夹层均可行、安全、有效。
- 需更长期研究评估Ankura Plus支架的稳健性和适用性。
研究设计与样本
- 回顾性分析2020年1月至2022年10月纳入的54例Stanford B型主动脉夹层患者,其中Ankura Plus支架组16例,Castor支架组38例。
主要发现
- 两组手术成功率均为100%,住院期间无内漏或死亡。
- Ankura Plus组手术时间长于Castor组(122.6±5.1 vs. 103.7±10.0,P<0.001)。
- 平均随访12个月,两组主支架及分支支架通畅率均为100%,真腔直径显著增加、假腔直径缩小,假腔完全血栓形成概率无统计学显著差异(68.8% vs. 67.6%,P=0.993)。
- Ankura Plus组与Castor组肾功能衰竭发生率(6.3% vs. 8.1%,P=0.814)、卒中发生率(6.3% vs. 2.7%,P=0.520)、内漏发生率(6.3% vs. 10.5%,P=0.621)均无统计学显著差异。
- Castor组1例因I型内漏术后3个月再干预,1例术后4个月死于肾功能衰竭;Ankura Plus组1例因主支架远端真腔狭窄术后1个月追加覆膜支架。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需更长期研究评估Ankura Plus支架的稳健性和适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the efficacy and safety of the Ankura Plus and Castor stents in Stanford type B aortic dissection (TBAD) with an insufficient proximal anchoring area. METHODS: Between January 2020 and October 2022, 54 patients with TBAD were enrolled, including 16 patients with Ankura Plus stents and 38 patients with Castor stents. Data from the 2 stents were retrospectively analyzed. RESULTS: The surgical success rate for both stents was 100%, and no endoleaks or deaths occurred during hospitalization. The Ankura Plus stent group had a longer surgery time than the Castor stent group (122.6 ± 5.1 vs. 103.7 ± 10.0, P < 0.001). After an average follow-up of 12 months, the patency rates of the main and branch stents were 100% in both groups. The diameter of the true lumen (TL) was significantly increased, the diameter of the false lumen (FL) was reduced, and there was no statistically significant difference in the probability of complete thrombosis of the FL (68.8% vs. 67.6%, P = 0.993). There were no significant differences in the incidences of renal failure (6.3% vs. 8.1%, P = 0.814), stroke (6.3% vs. 2.7%, P = 0.520), or endoleaks (6.3% vs. 10.5%, P = 0.621) between the Ankura Plus and Castor stent groups. One patient in the Castor stent group underwent reintervention because of a type I endoleak 3 months after surgery. One patient in the Ankura Plus stent group had an additional covered stent placed after 1 month due to distal TL stenosis of the main stent. One patient in the Castor stent group died of renal failure 4 months after surgery. CONCLUSIONS: Both the Ankura Plus and Castor stents are feasible, safe, and effective in the treatment of TBAD with an insufficient proximal anchoring area. Additional long-term studies are required to evaluate the robustness and applicability of Ankura Plus stents.
引用
- Liu B, Zhang L, Liu P, et al. Comparison of the Novel Ankura Plus Stent and Castor Stent for the Treatment of Stanford Type B Aortic Dissection with an Insufficient Proximal Anchoring Area. Ann Vasc Surg. 2024. PMID: 39341554. doi:10.1016/j.avsg.2024.07.114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。